目的 分析艾地苯醌聯(lián)合奧拉西坦治療老年阿爾茨海默病患者的臨床療效。方法 選擇2016年7月-2018年7月開灤總醫(yī)院收治的老年阿爾茨海默病患者57例作為研究對象，根據(jù)治療方法差異將患者分為對照組（30例）和觀察組（27例）。對照組口服奧拉西坦膠囊，0.8 g/次，3次/d。觀察組在對照組基礎(chǔ)上口服艾地苯醌片，30 mg/次，3次/d。3個月為1療程，兩組均治療2個療程。觀察兩組患者的臨床療效，同時比較兩組治療前后的蒙特利爾認(rèn)知評估量表（MoCA）評分、日常生活能力量表（ADL）評分和神經(jīng)精神科量表（NPI）評分。結(jié)果 治療后，觀察組總有效率為85.19%，顯著高于對照組的60.00%，兩組比較具有統(tǒng)計學(xué)意義（P<0.05）。隨著治療時間延長，兩組患者M(jìn)oCA評分均顯著提升（P<0.05），但觀察組MoCA評分明顯高于同時期對照組（P<0.05）。隨著治療時間延長，兩組患者ADL評分均顯著降低（P<0.05），但觀察組ADL評分明顯低于同時期對照組（P<0.05）。治療后，觀察組患者NPI評分低于治療前（P<0.05），且觀察組治療后NPI評分顯著低于對照組（P<0.05）。結(jié)論 艾地苯醌聯(lián)合奧拉西坦治療老年阿爾茨海默病效果顯著，且能有效改善患者認(rèn)知及行為能力，改善精神癥狀，同時用藥安全性較高。

Objective To analyze the clinical effect of idebenone combined with oxiracetam in treatment of senile Alzheimer's disease. Methods Fifty-seven elderly patients with Alzheimer's disease admitted to Kailuan General Hospital from July 2016 to July 2018 were selected as study subjects, and the patients were divided into control group (30 cases) and observation group (27 cases) according to the differences in treatment methods. Patients in the control group were po administered with Oxiracetam Capsules, 0.8 g/time, and 3 times daily. Patients in the observation group were po administered with Idebenone Tablets on the basis of control group, 30 mg/time, 3 times daily. Three months for one course of treatment, the two groups were treated for two courses. The clinical efficacy in two groups was observed, and the MoCA, ADL, and NPI scores in two groups before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 85.19%, which was significantly higher than 60.00% in the control group, and the comparison between two groups was statistically significant (P<0.05). With the extension of treatment time, the MoCA score in two groups was significantly increased (P<0.05), but the MoCA score in the observation group was significantly higher than that of the control group (P<0.05). With the extension of treatment time, The ADL score in two groups significantly decreased (P<0.05), but the ADL score of the observation group was significantly lower than that of the control group at the same time (P<0.05). After treatment, the NPI score of patients in the observation group was lower than that before treatment (P<0.05), and the NPI score of patients in the observation group was significantly lower than that of the control group (P<0.05). Conclusion Idebenone combined with oxiracetam in treatment of senile Alzheimer's disease has a significant effect, and can effectively improve the cognitive and behavioral ability of patients, improve mental symptoms, at the same time, the drug safety is higher.

R971

河北省醫(yī)學(xué)科學(xué)研究計劃項目（20191322）